Michael J. Eck

Michael J. Eck

Auto-generated profile, based on publicly available information

Michael J. Eck

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in Nature
Verified
Journal Article
Closed access
PDF file
EPEunyoung Park
Eunyoung Park
SRShaun Rawson
Shaun Rawson
KLKunhua Li
Kunhua Li
BKByeong-Won Kim
Byeong-Won Kim
SFScott B. Ficarro
Scott B. Ficarro
MEMichael J. Eck
Michael J. Eck

1 July 2019 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
CTCiric To
Ciric To
JJJaebong Jang
Jaebong Jang
TCTing Chen
Ting Chen
EPEunyoung Park
Eunyoung Park
MMMierzhati Mushajiang
Mierzhati Mushajiang
PJPasi Antero Jänne
Pasi Antero Jänne
Allosteric kinase inhibitors offer a potentially complementary therapeutic strategy to ATP-competitive kinase inhibitors due to their distinct sites of target binding. In this study, we identify and study a mutant-selective EGFR allosteric inhibitor, JBJ-04-125-02, which as a single agent can inhibit cell proliferation and EGFRL858R/T790M/C797S signaling in vitro and in vivo. However, increased EGFR dimer formation limits treatment efficacy and leads to drug resistance. Remarkably, osimertinib, an ATP-competitive covalent EGFR inhibitor, uniquely and significantly enhances the binding of JBJ-04-125-02 for mutant EGFR. The combination of osimertinib and JBJ-04-125-02 results in an increase in apoptosis, a more effective inhibition of cellular growth, and an increased efficacy in vitro and in vivo compared with either single agent alone. Collectively, our findings suggest that the combination of a covalent mutant–selective ATP-competitive inhibitor and an allosteric EGFR inhibitor may be an effective therapeutic approach for patients with EGFR-mutant lung cancer. Significance: The clinical efficacy of EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer is limited by acquired drug resistance, thus highlighting the need for alternative strategies to inhibit EGFR. Here, we identify a mutant EGFR allosteric inhibitor that is effective as a single agent and in combination with the EGFR TKI osimertinib. This article is highlighted in the In This Issue feature, p. 813

14 April 2022 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
CTCiric To
Ciric To
TBTyler S. Beyett
Tyler S. Beyett
JJJaebong Jang
Jaebong Jang
WFWilliam Feng
William Feng
MBMagda Bahcall
Magda Bahcall
PJPasi Antero Jänne
Pasi Antero Jänne

19 September 2017 in eLife
Verified
Journal Article
Open access
HHHai-Tsang Huang
Hai-Tsang Huang
HSHyuk-Soo Seo
Hyuk-Soo Seo
TZTinghu Zhang
Tinghu Zhang
YWYubao Wang
Yubao Wang
BJBaishan Jiang
Baishan Jiang
NGNathanael S Gray
Nathanael S Gray
Thorough preclinical target validation is essential for the success of drug discovery efforts. In this study, we combined chemical and genetic perturbants, including the development of a novel selective maternal embryonic leucine zipper kinase (MELK) inhibitor HTH-01-091, CRISPR/Cas9-mediated MELK knockout, a novel chemical-induced protein degradation strategy, RNA interference and CRISPR interference to validate MELK as a therapeutic target in basal-like breast cancers (BBC). In common culture conditions, we found that small molecule inhibition, genetic deletion, or acute depletion of MELK did not significantly affect cellular growth. This discrepancy to previous findings illuminated selectivity issues of the widely used MELK inhibitor OTSSP167, and potential off-target effects of MELK-targeting short hairpins. The different genetic and chemical tools developed here allow for the identification and validation of any causal roles MELK may play in cancer biology, which will be required to guide future MELK drug discovery efforts. Furthermore, our study provides a general framework for preclinical target validation.

9 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TBTyler S. Beyett
Tyler S. Beyett
CTCiric To
Ciric To
DHDavid E. Heppner
David E. Heppner
JRJaimin K. Rana
Jaimin K. Rana
ASAnna Margaret Schmoker
Anna Margaret Schmoker
MEMichael J. Eck
Michael J. Eck
Lung cancer is frequently caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric EGFR inhibitors offer promise as the next generation of therapeutics, as they are unaffected by common ATP-site resistance mutations and synergize with the drug osimertinib. Here, we examine combinations of ATP-competitive and allosteric inhibitors to better understand the molecular basis for synergy. We identify a subset of irreversible EGFR inhibitors that display positive binding cooperativity and synergy with the allosteric inhibitor JBJ-04-125-02 in several EGFR variants. Structural analysis of these complexes reveals conformational changes occur mainly in the phosphate-binding loop (P-loop). Mutation of F723 in the P-loop reduces cooperative binding and synergy, supporting a mechanism in which F723-mediated contacts between the P-loop and the allosteric inhibitor are critical for synergy. These structural and mechanistic insights will aid in the identification and development of additional inhibitor combinations with potential clinical value.

7 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GPGonzalo Luis Gonzalez-Del Pino
Gonzalo Luis Gonzalez-Del Pino
KLKunhua Li
Kunhua Li
EPEunyoung Park
Eunyoung Park
ASAnna Margaret Schmoker
Anna Margaret Schmoker
BHByung Hak Ha
Byung Hak Ha
MEMichael J. Eck
Michael J. Eck
Significance: Drugs that inhibit specific kinases now represent one of the main classes of targeted therapies. A majority of drug development efforts in this space focus on a given kinase in isolation as the target. However, our work demonstrates that in the context of the RAF/MEK/ERK pathway, the relevant target for compounds developed as allosteric MEK inhibitors (MEKi) is not free MEK but RAF/MEK complexes. Because signaling through this pathway is essential in normal tissues, indiscriminate blockade of all MEK activity is not tolerated. Our findings imply that selective inhibition of specific RAF/MEK complexes is an accessible route for development of new MEKi, and they provide a biophysical foundation for better understanding and applying current clinical agents.